CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Group 1 - The company is closely monitoring the rising biotech innovation landscape in China and its implications for CG Oncology's competitive position [1] - In 2019, the company partnered with Lepu Biopharma, a Chinese pharmaceutical firm, to advance its product cretostimogene, which allows the company to maintain a connection to the evolving market in China [1] - The focus for U.S. companies should be on novel disruptive innovations that cater to a largely untapped U.S. population, which presents significant opportunities for growth [1]